Biography
Professor Angus Dalgleish studied medicine at University College London where he obtained an MBBS and a BSc in Anatomy. He is a Fellow of The Royal College of Physicians of the UK and Australia, Royal College of Pathologists and The Academy of Medical Scientists. After graduating he spent a year in the flying doctor service in Queensland. He also trained in Internal Medicine and Oncology in Brisbane and Sydney.
Following an interest in how viruses caused cancer, he commenced an MD with Professor Robin Weiss, FRS at the Institute of Cancer Research and Royal Marsden Hospital. Following five years as a clinical scientist at the Medical Research Council’s clinical research centre in Northwick Park, he was appointed to the Foundation Chair in Oncology at St. George’s University of London in 1991. There his main interest has been the immunology of cancer and the development of immunotherapies to treat, in particular, melanoma.
Prof Dalgleish revived thalidomide as an anti-cancer agent, leading to the development of lenalidomide and pomalidomide, now widely used for myeloma and lymphoma. He introduced IL-2 for melanoma treatment in the UK and advanced cancer vaccines using heat-killed mycobacteria like M. vaccae and M. obuense (IMM-101). His work also includes repurposing drugs such as low-dose naltrexone and emphasizing vitamin D3’s role in cancer.
He is the author or co-author of over 500 peer reviewed scientific papers and over 70 chapters in medical books. He is the co-editor of five medical books and has been principal of the Institute for Cancer vaccines and Immunotherapy(ICVI) since 2000.